

**NEW!  
NON-AVIAN  
FORMULA**

**IN THE TREATMENT  
OF OSTEOARTHRITIS  
OF THE KNEE**

**REPLACE WHAT'S MISSING™**




**ORTHO VISC®**  
HIGH MOLECULAR WEIGHT HYALURONAN



# ORTHOVISC®: DEMONSTRATED RELIEF IN PATIENTS WITH MILD TO MODERATE OA OF THE KNEE

- 6-month durability of symptom relief with 3 injections<sup>1</sup>
- Ultrapure natural hyaluronan with highest HA concentration per injection<sup>2-6</sup>
- No pseudoseptic reactions reported in more than 1 million injections\*
- Repeat courses may be safely administered<sup>2</sup>
- Can be prescribed to patients with known avian allergies



ORTHOVISC Ordering Information
Product Code 277500
DePuy Mitek Customer Service: 1-800-382-4682
Monday–Friday 8:30 AM to 6:30 PM EST

2008 ORTHOVISC Coding Information
HCPCS Code J 7324
CPT Code 20610
Visit our Web site: <a href="http://www.orthovisc.com">www.orthovisc.com</a>

**Important Safety Information:** ORTHOVISC® is indicated in the treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative nonpharmacologic therapy and to simple analgesics, eg, acetaminophen. In clinical studies, the most commonly reported adverse events (AEs) were arthralgia, back pain, and headache. Other side effects included local injection site AEs. ORTHOVISC® is contraindicated in patients with known hypersensitivity to hyaluronate formulations or known hypersensitivity (allergy) to gram positive bacterial proteins. ORTHOVISC® should not be injected in patients with infections or skin diseases in the area of the injection site or joint. Strict aseptic technique should be used. The effectiveness of more than 1 course has not been established.

**References:** 1. Brandt KD, Block JA, Michalski JP, et al. Efficacy and safety of intraarticular sodium hyaluronate in knee osteoarthritis. *Clin Orthop Relat Res.* 2001;385:130-143. 2. Orthovisc® (high molecular weight hyaluronan) manufacturer's full Prescribing Information. 3. Synvisc® (hyal G-F 20) manufacturer's full Prescribing Information. 4. Hyalgan® (sodium hyaluronate) manufacturer's full Prescribing Information. 5. Supartz® (sodium hyaluronate) manufacturer's full Prescribing Information. 6. Euflexxa™ (1% sodium hyaluronate) manufacturer's full Prescribing Information. 7. Adams ME. Viscosupplementation as articular therapy. In: Laurent TC, ed. *The Chemistry, Biology and Medical Applications of Hyaluronan and its Derivatives.* London, England: Portland Press Ltd.; 1998:244-253. 8. Mazzucco D, McKinley G, Scott RD, Spector M. Rheology of joint fluid in total knee arthroplasty patients. *J Orthop Res.* 2002;20(6):1157-1163. 9. Adams ME, Lussier AJ, Peyron JG. A risk-benefit assessment of injections of hyaluronan and its derivatives in the treatment of osteoarthritis of the knee. *Drug Saf.* 2000;23(2):115-130.

CPT and HCPCS codes are supplied for informational purposes only and represent no statement, promise, or guarantee by DePuy Mitek, Inc. that these codes will be appropriate or reimbursement will be made.

\*MedLine and FDA Maude/MDR database searches, February 2008.

**ORTHOVISC®**  
HIGH MOLECULAR WEIGHT HYALURONAN

Please see full Prescribing Information available from your sales representative.